1
Eversense E3 CGM Quick Reference Guide
Indications for Use
The Eversense E3 CGM System is intended
for continually measuring interstitial glucose
levels in adults (18 years and older) with
diabetes for up to 180 days. The system
is indicated for use to replace fingerstick
blood glucose measurements for diabetes
treatment decisions.
The system is intended to:
• Provide real-time glucose readings.
• Provide glucose trend information.
• Provide alerts for the detection and
prediction of episodes of low blood
glucose (hypoglycemia) and high blood
glucose (hyperglycemia).
• The system is a prescription device.
Historical data from the system can be
interpreted to aid in providing therapy
adjustments. These adjustments should
be based on patterns and trends seen
over time.
• The system is intended for single
patient use.
Refer to the Eversense E3 CGM User Guide for more detailed information.
Contraindications
• The system is contraindicated in people for
whom dexamethasone or dexamethasone
acetate may be contraindicated.
• The smart transmitter is incompatible
with magnetic resonance imaging (MRI)
procedures. The smart transmitter is
MR Unsafe and MUST BE REMOVED before
undergoing an MRI (magnetic resonance
imaging) procedure. The sensor is MR
Conditional. For more information on the
sensor, see MRI Safety Information in the
Eversense E3 CGM System User Guide.
• Mannitol or sorbitol, when administered
intravenously, or as a component of an
irrigation solution or peritoneal dialysis
solution, may increase blood mannitol or
sorbitol concentrations and cause falsely
elevated readings of your sensor glucose
results. Sorbitol is used in some artificial
sweeteners, and concentration levels from
typical dietary intake do not impact sensor
glucose results.
To Next Page
Loading...
